133 related articles for article (PubMed ID: 33355042)
1. Comprehensive Bioinformatics Analysis of Key Methyltransferases and Demethylases for Histone Lysines in Hepatocellular Carcinoma.
Zheng Y; Tang L; Chen G; Liu Z
Technol Cancer Res Treat; 2020; 19():1533033820983284. PubMed ID: 33355042
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
[TBL] [Abstract][Full Text] [Related]
3. Controllers of histone methylation-modifying enzymes in gastrointestinal cancers.
Li L; Song Q; Zhou J; Ji Q
Biomed Pharmacother; 2024 May; 174():116488. PubMed ID: 38520871
[TBL] [Abstract][Full Text] [Related]
4. Histone methylation: a dynamic mark in health, disease and inheritance.
Greer EL; Shi Y
Nat Rev Genet; 2012 Apr; 13(5):343-57. PubMed ID: 22473383
[TBL] [Abstract][Full Text] [Related]
5. Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.
Pires-Luís AS; Vieira-Coimbra M; Vieira FQ; Costa-Pinheiro P; Silva-Santos R; Dias PC; Antunes L; Lobo F; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Epigenetics; 2015; 10(11):1033-43. PubMed ID: 26488939
[TBL] [Abstract][Full Text] [Related]
6. Trimethyllysine: From Carnitine Biosynthesis to Epigenetics.
Maas MN; Hintzen JCJ; Porzberg MRB; Mecinović J
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322546
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.
Tough DF; Lewis HD; Rioja I; Lindon MJ; Prinjha RK
Br J Pharmacol; 2014 Nov; 171(22):4981-5010. PubMed ID: 25060293
[TBL] [Abstract][Full Text] [Related]
8. H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression.
Rowbotham SP; Li F; Dost AFM; Louie SM; Marsh BP; Pessina P; Anbarasu CR; Brainson CF; Tuminello SJ; Lieberman A; Ryeom S; Schlaeger TM; Aronow BJ; Watanabe H; Wong KK; Kim CF
Nat Commun; 2018 Nov; 9(1):4559. PubMed ID: 30455465
[TBL] [Abstract][Full Text] [Related]
9. Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin.
Hu X; Dong M; Liang X; Liu Z; Li Q
Int J Nanomedicine; 2021; 16():471-480. PubMed ID: 33500617
[TBL] [Abstract][Full Text] [Related]
10. ASH1L-MRG15 methyltransferase deposits H3K4me3 and FACT for damage verification in nucleotide excision repair.
Maritz C; Khaleghi R; Yancoskie MN; Diethelm S; Brülisauer S; Ferreira NS; Jiang Y; Sturla SJ; Naegeli H
Nat Commun; 2023 Jul; 14(1):3892. PubMed ID: 37393406
[TBL] [Abstract][Full Text] [Related]
11. Novel
Tembrink M; Gerding WM; Wieczorek S; Mika T; Schroers R; Nguyen HP; Vangala DB; Nilius-Eliliwi V
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296904
[TBL] [Abstract][Full Text] [Related]
12. A Computational Approach to Predict the Role of Genetic Alterations in Methyltransferase Histones Genes With Implications in Liver Cancer.
Aravena TI; Valdés E; Ayala N; D'Afonseca V
Cancer Inform; 2023; 22():11769351231161480. PubMed ID: 37008071
[TBL] [Abstract][Full Text] [Related]
13. Identification of a transcriptional signature found in multiple models of ASD and related disorders.
Thudium S; Palozola K; L'Her É; Korb E
Genome Res; 2022 Sep; 32(9):1642-54. PubMed ID: 36104286
[TBL] [Abstract][Full Text] [Related]
14. Structural insight into ASH1L PHD finger recognizing methylated histone H3K4 and promoting cell growth in prostate cancer.
Yu M; Jia Y; Ma Z; Ji D; Wang C; Liang Y; Zhang Q; Yi H; Zeng L
Front Oncol; 2022; 12():906807. PubMed ID: 36033518
[TBL] [Abstract][Full Text] [Related]
15. Histone H3K36me2-Specific Methyltransferase ASH1L Promotes MLL-AF9-Induced Leukemogenesis.
Aljazi MB; Gao Y; Wu Y; Mias GI; He J
Front Oncol; 2021; 11():754093. PubMed ID: 34692539
[TBL] [Abstract][Full Text] [Related]
16. Circulating miR-122-5p, miR-92a-3p, and miR-18a-5p as Potential Biomarkers in Human Liver Transplantation Follow-Up.
Morsiani C; Collura S; Sevini F; Ciurca E; Bertuzzo VR; Franceschi C; Grazi GL; Cescon M; Capri M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834868
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
18. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies.
Gutiérrez-Cuevas J; Lucano-Landeros S; López-Cifuentes D; Santos A; Armendariz-Borunda J
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612019
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic remodelling in human hepatocellular carcinoma.
Braghini MR; Lo Re O; Romito I; Fernandez-Barrena MG; Barbaro B; Pomella S; Rota R; Vinciguerra M; Avila MA; Alisi A
J Exp Clin Cancer Res; 2022 Mar; 41(1):107. PubMed ID: 35331312
[TBL] [Abstract][Full Text] [Related]
20. Construction of a Myc-associated ceRNA network reveals a prognostic signature in hepatocellular carcinoma.
Zhang DD; Shi Y; Liu JB; Yang XL; Xin R; Wang HM; Wang PY; Jia CY; Zhang WJ; Ma YS; Fu D
Mol Ther Nucleic Acids; 2021 Jun; 24():1033-1050. PubMed ID: 34141458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
